On the occasion of the ASCO congress (American society of Clinical Cancer), Pr. Eric Raymond has shown the positive results of a worldwide study of immunotherapy for oesophageal cancer. When tislelizumab, a new immunotherapy antibody, is given with the usual chemotherapy, it significantly improves the patient survival with a 34% lower risk of death.